-
IVERIC bio NASDAQ:ISEE IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases.
Location: 1 Penn Plz Fl 35, New York, 10119-0002, US | Website: www.ivericbio.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Short % of Float
12.15%
Insider Ownership
0.66%
Institutional Own.
-
Qtr Updated
03/31/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
IZERVAY™ (avacincaptad pegol intravitreal solution) Details Age-related macular degeneration, Eye disease , Geographic atrophy | Approved Quarterly sales | |
Zimura (avacincaptad pegol) Details Macular degeneration, Autoimmune disease, Inflammatory disease | Phase 2b Update |